Diffinity Genomics, a Rochester–based biotechnology company, has a new president. The company announced on Friday that Joseph Marasco would assume the role.
Diffinity CEO Jeffrey Helfer will step down from his position and from the company’s board of directors. Marasco has been appointed to the board to fill the vacancy.
Helfer will continue in a new product and business development role and as an executive adviser through the leadership transition.
(Sponsored)
Criminal Liability for Employment Law Violations?
New York employers are often surprised to learn that wage law violations can lead to criminal penalties in addition to financial penalties. Whether payroll is outsourced, or a staffing agency
Maximizing Tax Benefits for Energy-Efficient Buildings
The Inflation Reduction Act (IRA) of 2022 significantly enhanced the Section 179D deduction, making it even more valuable for businesses investing in energy-efficient commercial building property (EECBP) and energy-efficient commercial
Since 2007, Marasco has been CEO of Chiral Quest Corp., a fine chemical and active pharmaceutical ingredient manufacturing firm. He has held leadership roles at early-stage and publicly traded firms including Dow Chemical, Beckman, and Kaneka, according to Diffinity.
The changes are part of Diffinity’s succession plan to help ensure it has access to the expertise necessary for its present growth stage, according to the company.
Diffinity has received investment from Central New York sources including the Syracuse–based Seed Capital Fund of CNY, LLC and the Allyn Family Capital Fund, LLC. The company develops products used in isolating and analyzing nucleic acids like DNA.
It’s work that life-sciences professionals perform on a regular basis. The company’s first two products are pipette tips used to move liquids in a laboratory setting.
The tips contain a proprietary material created using nanotechnology that allows for rapid purification of samples, according to Diffinity.
Contact Tampone at ktampone@cnybj.com
